Nana Esi Kittah, MD
Endocrinology, Diabetes & Metabolism · Las Vegas, NVNPI 1922231745
Payments from drug & device makers
Across 12 payments — averaging $32.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$139
- Sanofi-aventis U.S. LLC$91
- Dexcom, Inc.$69
- Novo Nordisk$33
- Abbott$32
- Radius Health, Inc.$15
- plus $12 from 1 others
What the payments were for
- Food & beverage$35792%
- Education$338%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $139 |
| Sanofi-aventis U.S. LLC | 1 | $91 |
| Dexcom, Inc. | 3 | $69 |
| Novo Nordisk | 2 | $33 |
| Abbott | 1 | $32 |
| Radius Health, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$123
How this compares
$390 in reported general payments places this provider in the 5th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
See all endocrinology, diabetes & metabolism providers in Nevada →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 224 | $388,803 |
| OzempicSemaglutide | 168 | $384,072 |
| JardianceEmpagliflozin | 195 | $284,710 |
| ProliaDenosumab | 133 | $234,080 |
| TrulicityDulaglutide | 76 | $156,368 |
| RybelsusSemaglutide | 29 | $75,243 |
| JanuviaSitagliptin Phosphate | 48 | $62,825 |
| FarxigaDapagliflozin Propanediol | 47 | $62,500 |
| Tresiba Flextouch U-100Insulin Degludec | 57 | $56,415 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 18 | $39,586 |
| Novolog FlexpenInsulin Aspart | 95 | $38,320 |
| TradjentaLinagliptin | 30 | $37,485 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 168 | $34,452 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $32,629 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 24 | $31,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $33 | $475,896248 claims |
| AstraZenecaFarxiga | $139 | $62,50047 claims |
| Radius Health, Inc.Tymlos | $15 | $28,51611 claims |
| Sanofi-aventis U.S. LLCLantus | $91 | $16,13154 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
Other endocrinology, diabetes & metabolism in Las Vegas
- Samer NakhleLas Vegas$14.5M
- Betsy PalalLas Vegas$6.8M
- Chakravarthy KannanLas Vegas$144K
- Michael UzmannLas Vegas$77K
- Molouk RahnemaLas Vegas$73K
- Nicholas VernettiLas Vegas$62K
- Firhaad IsmailLas Vegas$47K
- Bijan AhrariLas Vegas$47K
- Freddie ToffelLas Vegas$33K
- Mary Ann MartinLas Vegas$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.